Sridevi Rajeeve

14PUBLICATIONS
78CO-AUTHORS
Haematological tumoursMedical bacteriologyPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jul 29, 2026
Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma.

|Jul 20, 2026
Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool.

|May 01, 2026
A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patients.

|Apr 12, 2026
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma.

Hamza Hashmi, Tara Sebastian, Sridevi Rajeeve

|Nov 02, 2025
Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma.

Eric Jurgens, Tala Shekarkhand, Colin Rueda

|Oct 13, 2025
Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.

Tara Sebastian, Sridevi Rajeeve, Tasmin Farzana

Pageof 3

Frequent Collaborators

11 joint publications

Kylee Maclachlan

11 joint publications

Urvi Shah

11 joint publications

Malin L Hultcrantz

10 joint publications

Sergio Giralt